Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBT (2016 - 2025)

Historic EBT for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$2.2 million.

  • Anika Therapeutics' EBT fell 78800.0% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.3 million, marking a year-over-year decrease of 15048.05%. This contributed to the annual value of -$4.1 million for FY2024, which is 22921.42% down from last year.
  • Anika Therapeutics' EBT amounted to -$2.2 million in Q3 2025, which was down 78800.0% from -$4.0 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' EBT ranged from a high of $25.3 million in Q4 2023 and a low of -$12.0 million during Q1 2023
  • Its 5-year average for EBT is -$90157.9, with a median of -$2.2 million in 2025.
  • Per our database at Business Quant, Anika Therapeutics' EBT soared by 35115.19% in 2022 and then crashed by 78800.0% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' EBT stood at -$6.6 million in 2021, then skyrocketed by 351.15% to $16.7 million in 2022, then soared by 51.56% to $25.3 million in 2023, then plummeted by 105.04% to -$1.3 million in 2024, then plummeted by 75.37% to -$2.2 million in 2025.
  • Its EBT was -$2.2 million in Q3 2025, compared to -$4.0 million in Q2 2025 and -$3.9 million in Q1 2025.